---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-094433"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2026-08-12T10:59:47+00:00"
generated_at: "2026-08-12T11:05:38.385576+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Protalix Q2 2026: YTD revenue $53.6M, net income $22.1M; Elfabrio patent extended to 2035

## Summary
- Q2 goods revenue $19.8M, up $4.4M YoY on Elfabrio sales; YTD total revenue $53.6M vs $25.8M in 2025
- Year-to-date net income $22.1M, achieving profitability; cash and short-term deposits $40.7M at June 30, 2026
- FY2026 revenue guidance reaffirmed at $78-83M incl. $25M Chiesi milestone; Elfabrio $33-35M, Elelyso $20-23M
- USPTO extended Elfabrio US patent to Nov 17, 2035 (May 4, 2026); South Korea orphan drug designation + MA granted May 2026
- PRX-115 Phase 2 RELEASE enrollment ongoing; top-line results expected H2 2027; USPTO issued uricase patent July 7, 2026

## SEC filing metadata
- accession: 0001104659-26-094433
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2026-08-12T10:59:47+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000110465926094433/0001104659-26-094433-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000110465926094433/plx-20260812x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-094433
- JSON: https://secwatch.observer/filing/0001104659-26-094433.json
- Plain text: https://secwatch.observer/filing/0001104659-26-094433.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.